AM-679

AM-679 is a synthetic cannabinoid that is structurally related to AB-PINACA and AB-FUBINACA. It was first identified in Japan in 2012, and has since been found in synthetic cannabis products around the world. AM-679 is a potent agonist of the CB1 receptor and CB2 receptor, and its use has been associated with serious adverse health effects.

Chemistry

AM-679 is a synthetic cannabinoid, which means it is a chemical compound that mimics the effects of natural cannabinoids found in the cannabis plant. It is structurally related to other synthetic cannabinoids such as AB-PINACA and AB-FUBINACA. The chemical structure of AM-679 includes a 1-amino-3-methyl-1-oxobutane group, which is where it gets its name.

Pharmacology

AM-679 acts as a potent agonist of the CB1 and CB2 receptors, which are part of the endocannabinoid system in the human body. This system plays a role in a variety of physiological processes, including pain sensation, mood, and memory. By activating these receptors, AM-679 can produce effects similar to those of natural cannabinoids.

Adverse effects

The use of AM-679 has been associated with serious adverse health effects. These can include severe agitation, rapid heart rate, high blood pressure, seizures, and in some cases, death. Because AM-679 is often found in synthetic cannabis products, these adverse effects can occur in individuals who believe they are using natural cannabis.

Legal status

In many countries, including the United States, AM-679 is a controlled substance. This means it is illegal to manufacture, distribute, or possess the drug without a license. In some jurisdictions, it is also illegal to use AM-679 recreationally.

See also

• Synthetic cannabinoids
• Cannabinoid receptor
• Endocannabinoid system

AM-679 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski